ArticleImmunity, inflammation and disease2025
Immunosuppression Efficacy via Nonlinear Modeling and Probabilistic Analysis of Human Leukocyte Antigen Match and Dose Effects on Allograft Rejection Risk.
Article in Immunity, inflammation and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immunosuppression Efficacy via Nonlinear Modeling and Probabilistic Analysis of Human Leukocyte Antigen Match and Dose Effects on Allograft Rejection Risk.Immunity, inflammation and disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHuman Leukocyte Antigen (HLA) compatibility is a key driver of kidney allograft outcomes, yet how matching interacts with immunosuppressant dosing remains unclear. This study evaluates whether low-resolution HLA match fractions affect mean dosing and quantified the joint impact of match quality and dose on rejection risk.
methodsIn 519 transplants grouped by HLA match (0-1.0 in 7 strata), full data completeness and variance homogeneity is confirmed, followed by the usage of one-way ANOVA to compare mean doses. Ridge-penalized logistic regression models was fitted at each match level to predict rejection probability across low- and high-dose regimens, deriving absolute and relative risk reductions.
resultsANOVA showed no significant dosing differences by match (F
conclusionUniform baseline dosing eliminates bias, allowing clear attribution of benefit to immunologic compatibility. These findings endorse a risk-tailored immunosuppression approach intensifying doses where match is low and potentially reducing them in highly compatible transplants and identify match ranges that maximize rejection prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.